Citations

Clear

3030 citation(s) found for "Susan, M".

Prognostic Value of Treadmill Exercise Testing in Elderly Persons
Goraya, Tauqir, Jacobsen, Steven J. , Pellikka, Patricia A. , Miller, Todd D., Khan, Akbar, Weston, Susan A., Roger, Véronique L. , Gersh, Bernard J. , Pellikka, Patricia A

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 132 | Issue: 11 | Pages: 862-870

10.7326/0003-4819-132-11-200006060-00003 | PMID 10836912 Get It

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006
Rimawi, Mothaffar F. , Forero, Andres , Nanda, Rita , Rodriguez, Angel , Pavlick, Anne C. , Osborne, C. Kent , Mayer, Ingrid A. , Goetz, Matthew P. , Wang, Tao , Hilsenbeck, Susan Galloway , Gutiérrez, Carolina , Schiff, Rachel , Chang, Jenny C. , Rimawi, Mothaffar

Mayo Clinic

Journal of Clinical Oncology | April 8, 2013 | Volume: 31 | Issue: 14 | Pages: 1726-1731

10.1200/jco.2012.44.8027 | PMID 23569315 Get It

Purpose We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)– amplified human xenografts in mice by inhibition of the HER2 pathway with lapatinib and trastuzumab to block all homo- and heterodimer signaling as well as by blockade of estrogen receptor (ER) when expressed. In this clinical trial, we sought to translate these findings to patients using targeted therapy without chemotherapy. Patients and Methods Women with stages II to III HER2-positive breast cancers were eligible. They received trastuzumab once per week (4 mg/kg loading, then 2 mg/kg) and lapatinib 1000 mg once per day for 12 weeks. Women with ER-positive tumors also received letrozole (plus a luteinizing hormone–releasing hormone [LHRH] agonist if premenopausal). Pathologic response was assessed by ER status. Biopsies were obtained at baseline, weeks 2 and 8, and time of surgery. Results Sixty-six patients were enrolled, and 64 were eligible and evaluable for response. Median tumor size was 6 cm (range, 1.5 to 30 cm). Adverse events were mainly grades 1 to 2 (GI, 63%; skin, 46%). Grade 3 metabolic, GI, and liver (18%; 12 patients) and grade 4 liver toxicities (one patient) were also observed. Overall, in-breast pathologic complete response (pCR; yp T 0 - is ) was 27% (ER positive, 21%; ER negative, 36%). The rate of low-volume residual disease ( yp T 1a-b ) was 22% (ER positive, 33%; ER negative, 4%). Conclusion In patients with locally advanced HER2-positive breast cancer, our approach of targeted therapy only resulted in a high pCR rate without chemotherapy. Our data support the hypothesis that selected patients with HER2-positive tumors may not need chemotherapy, and more-complete blockade of HER receptors and ER is an effective strategy worthy of further study.
Feasibility of a Clinical Trial of Vision Therapy for Treatment of Amblyopia
Lyon, Don, Hopkins, Kristine B., Chu, Raymond, Tamkins, Susanna M. , Melia, B. Michele, Holmes, Jonathan M. , Repka, Michael X. , Wheeler, David T., Sala, Nicholas A., Dumas, Janette, Silbert, David I., Group, the Pediatric Eye Disease Investigator, Kulp, Marjean Taylor , Cotter, Susan A. , Group, the Pediatric Eye Disease Investigator, Holmes, Jonathan M.

Mayo Clinic

Optometry and Vision Science | April 5, 2013 | Volume: 90 | Issue: 5 | Pages: 475-481

10.1097/opx.0b013e31828def04 | PMID 23563444 Get It

ABSTRACT Purpose We conducted a pilot randomized clinical trial of office‐based active vision therapy for the treatment of childhood amblyopia to determine the feasibility of conducting a full‐scale randomized clinical trial. Methods A training and certification program and manual of procedures were developed to certify therapists to administer a standardized vision therapy program in ophthalmology and optometry offices consisting of weekly visits for 16 weeks. Nineteen children, aged 7 to less than 13 years, with amblyopia (20/40–20/100) were randomly assigned to receive either 2 hours of daily patching with active vision therapy or 2 hours of daily patching with placebo vision therapy. Results Therapists in diverse practice settings were successfully trained and certified to perform standardized vision therapy in strict adherence with protocol. Subjects completed 85% of required weekly in‐office vision therapy visits. Eligibility criteria based on age, visual acuity, and stereoacuity, designed to identify children able to complete a standardized vision therapy program and judged likely to benefit from this treatment, led to a high proportion of screened subjects being judged ineligible, resulting in insufficient recruitment. There were difficulties in retrieving adherence data for the computerized home therapy procedures. Conclusions This study demonstrated that a 16‐week treatment trial of vision therapy was feasible with respect to maintaining protocol adherence; however, recruitment under the proposed eligibility criteria, necessitated by the standardized approach to vision therapy, was not successful. A randomized clinical trial of in‐office vision therapy for the treatment of amblyopia would require broadening of the eligibility criteria and improved methods to gather objective data regarding the home therapy. A more flexible approach that customizes vision therapy based on subject age, visual acuity, and stereopsis might be required to allow enrollment of a broader group of subjects.
Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Yonas E. , Schneider, Lon S. , Gitlin, Laura N. , Smith, Gwenn S. , Evans, Jovier D., Lee, Michael K. , Porsteinsson, Anton P. , Lanctôt, Krista L. , Rosenberg, Paul B. , Sultzer, David L. , Francis, Paul T. , Brodaty, Henry , Padala, Prasad P., Onyike, Chiadikaobi, Ortiz, Luis Agüera, Vitiello, Michael V. , Yaffe, Kristine , Zee, Phyllis C. , Herrmann, Nathan , Ballard, Clive , Khin, Ni A. , Alfaro, Cara L., Murray, Patrick S. , Schultz, Susan K. , Lyketsos, Constantine G. , ISTAART, Neuropsychiatric Syndromes Professional Interest Area of, Miller, David S. , Bell, J. Simon , Padala, Prasad R. , Ancoli‐Israel, Sonia , Bliwise, Donald L. , Martin, Jennifer L. , Sweet, Robert A. , ISTAART, Neuropsychiatric Syndromes Professional Interest Area of, Lanctôt, Krista L , Brodaty, Henry , Ballard, Clive , Geda, Yonas E

Mayo Clinic

Alzheimer's & Dementia | April 4, 2013 | Volume: 9 | Issue: 5 | Pages: 602-608

10.1016/j.jalz.2012.12.001 | PMID 23562430 Get It

Abstract Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS‐PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome‐specific synthetic reviews and recommendations prepared by NPS‐PIA workgroups on depression, apathy, sleep, agitation, and psychosis.
Transient Ultrastructural Injury and Repair of Pulmonary Capillaries in Transplanted Rat Lung: Effect of Preservation and Reperfusion
Hall, Susan, Odom, N., McGregor, Christopher G.A. , Haworth, Sheila G.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | April 3, 2013 | Volume: 7 | Issue: 1 | Pages: 49-57

10.1165/ajrcmb/7.1.49 | PMID 1627336 Get It

Abstract A donor lung is injured during preservation and is generally thought to be further injured by reperfusion on transplantation. Donor lungs from 15 adult male Lewis rats preserved by flush perfusion with cold Marshall's solution at 4° C were examined by scanning and by quantitative transmission electron microscopy after 2, 4, or 7 h of storage at 4° C and after transplantation (syngeneic) at 4 or 12 h (six animals per time interval). During preservation of the donor lung, capillary morphology changed rapidly. Both endothelial cells and type I pneumonocytes thinned (surface/volume ratio increased by 2 h in both; P < 0.001). Pericapillary edema developed involving the blood-gas barrier. Basement membrane thickness increased significantly (P < 0.001). Occasional breakage of the endothelial cell sheet occurred after 4 h of preservation, but even after 7 h of preservation there was no evidence of irreversible cell damage. The lamellar bodies of type II pneumocytes aggregated. Changes increased in severity with increase in preservation time. After transplantation, type I and type II pneumonocytes recovered after 12 h, but it took longer for the endothelial cell morphology to recover. Edema decreased rapidly during the first 4 h, despite the number of adherent neutrophils increasing 3-fold. The pulmonary capillaries of the transplanted lung showed no structural evidence of additional reperfusion injury, indicating a satisfactory method of preservation.
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study
Hummel, Trent R. , Wagner, Lars M. , Ahern, Charlotte H., Fouladi, Maryam , McGovern, Renee M., Ames, Matthew M. , Gilbertson, Richard J. , Ingle, Ashish M., Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Horton, Terzah M.

Mayo Clinic

Pediatric Blood & Cancer | March 28, 2013 | Volume: 60 | Issue: 9 | Pages: 1452-1457

10.1002/pbc.24541 | PMID 23554030 Get It

Phase I Study of a Modified Regimen of 90 Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma
Meredith, Ruby F. , Shen, Sui , Knox, Susan J., Micallef, Ivana N. , Shah, Jatin J., LoBuglio, Albert F., Forero‐Torres, Andres , Vaklavas, Christos

Mayo Clinic

Cancer Biotherapy and Radiopharmaceuticals | March 26, 2013 | Volume: 28 | Issue: 5 | Pages: 370-379

10.1089/cbr.2012.1387 | PMID 23530878 Get It

Depression, Healthcare Utilization, and Death in Heart Failure
Moraska, Amanda R., Chamberlain, Alanna M. , Shah, Nilay D., Vickers, Kristin S. , Rummans, Teresa A. , Spertus, John A. , Weston, Susan A., McNallan, Sheila M, Redfield, Margaret M. , Roger, Véronique L. , Dunlay, Shannon M. , Chamberlain, Alanna M , Spertus, John A

Mayo Clinic

Circulation: Heart Failure | March 20, 2013 | Volume: 6 | Issue: 3 | Pages: 387-394

10.1161/circheartfailure.112.000118 | PMID 23512984 Get It

Background— The increasing prevalence of heart failure (HF) and high associated costs have spurred investigation of factors leading to adverse outcomes in patients with HF. Studies to date report inconsistent evidence on the link between depression and outcomes with only limited data on emergency department and outpatient visits. Methods and Results— Olmsted, Dodge, and Fillmore county, Minnesota residents with HF were prospectively recruited between October 2007 and December 2010 and completed a 1-time 9-item Patient Health Questionnaire for depression categorized as: none to minimal (Patient Health Questionnaire score, 0–4), mild (5–9), or moderate to severe (≥10). Andersen-Gill models were used to determine whether depression predicted hospitalizations and emergency department visits, whereas negative binomial regression models explored the association of depression with outpatient visits. Cox proportional hazards regression characterized the relationship between depression and all-cause mortality. Among 402 patients with HF (mean age, 73±13 years; 58% men), 15% had moderate to severe depression, 26% mild, and 59% none to minimal depression. During a mean follow-up of 1.6 years, 781 hospitalizations, 1000 emergency department visits, 15 515 outpatient visits, and 74 deaths occurred. After adjustment, moderate to severe depression was associated with nearly a 2-fold increased risk of hospitalization (hazard ratio, 1.79; 95% confidence interval, 1.30–2.47) and emergency department visits (hazard ratio, 1.83; 95% confidence interval, 1.34–2.50), a modest increase in outpatient visits (rate ratio, 1.20; 95% confidence interval, 1.00–1.45), and a 4-fold increase in all-cause mortality (hazard ratio, 4.06; 95% confidence interval, 2.35–7.01). Conclusions— In this prospective cohort study, depression independently predicted an increase in the use of healthcare resources and mortality. Greater recognition and management of depression in HF may optimize clinical outcomes and resource utilization.
Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome
White, Kristin L., Vierkant, Robert A. , Fogarty, Zachary C. , Charbonneau, Bridget, Block, Matthew S. , Chenevix‐Trench, Georgia , group;, for AOCS/ACS, Rossing, Mary Anne, Pearce, Celeste Leigh, Schildkraut, Joellen M. , Menon, Usha , Kjær, Susanne K. , Levine, Douglas A. , Culver, Hoda Anton, Whittemore, Alice S. , Lambrechts, Diether , Wentzensen, Nicolas , Kupryjańczyk, Jolanta , Chang‐Claude, Jenny , Bandera, Elisa V. , Høgdall, Estrid , Heitz, Florian , Kaye, Stanley B., Fasching, Peter A. , Campbell, Ian , Goodman, Marc T. , Bean, Yukie T., Lurie, Galina, Eccles, Diana , Hein, Alexander , Beckmann, Matthias W. , Ekici, Arif B. , Brown, Robert , Flanagan, James M. , Harter, Philipp , Schwaab, Ira, Høgdall, Claus , Lundvall, Lene, Olson, Sara H. , Orlow, Irene , Paddock, Lisa E. , Rudolph, Anja , Eilber, Ursula, Dansonka‐Mieszkowska, Agnieszka , Rzepecka, Iwona K. , Ziółkowska-Seta, Izabela, Brinton, Louise A. , García‐Closas, Montserrat , Despierre, Evelyn, Lambrechts, Sandrina, Vergote, Ignace , Walsh, Christine , Lester, Jenny, Sieh, Weiva , McGuire, Valerie , Rothstein, Joseph H. , Lubiński, Jan , Menkiszak, Janusz , Jensen, Allan , Gayther, Simon A. , Ramus, Susan J. , Wu, Anna H. , Pike, Malcolm C. , DenBerg, David Van, Terry, Kathryn L. , Vitonis, Allison F., Johnatty, Sharon E., DeFazio, Anna , Song, Honglin , Sellers, Thomas A. , Phelan, Catherine M., Kalli, Kimberly R., Cunningham, Julie M. , Goode, Ellen L. , Lambrechts, Diether , Pharoah, Paul D.P. , group;, for AOCS/ACS, Cramer, Daniel W. , Gronwald, Jacek , Karlan, Beth Y. , Pejovic, Tanja B. , Paul, James , Bois, Andreas du , Yang, Hannah , Ziogas, Argyrios , Cybulski, Cezary , Gentry‐Maharaj, Aleksandra , Berchuck, Andrew , Doherty, Jennifer A. , Tyrer, Jonathan P. , Fridley, Brooke L. , Fazio, Anna de , Rudolph, Anja , Lambrechts, Diether , Kjaer, Susanne K , Ramus, Susan J , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Orlow, Irene , Campbell, Ian G , Menkiszak, Janusz , Brown, Robert , Fogarty, Zachary C , Flanagan, James M , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , García-Closas, Montserrat , Ekici, Arif B , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T , Bandera, Elisa V.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 19, 2013 | Volume: 22 | Issue: 5 | Pages: 987-992

10.1158/1055-9965.epi-13-0028 | PMID 23513043 Get It

Abstract Background: Ovarian cancer is a leading cause of cancer-related death among women. In an effort to understand contributors to disease outcome, we evaluated single-nucleotide polymorphisms (SNP) previously associated with ovarian cancer recurrence or survival, specifically in angiogenesis, inflammation, mitosis, and drug disposition genes. Methods: Twenty-seven SNPs in VHL, HGF, IL18, PRKACB, ABCB1, CYP2C8, ERCC2, and ERCC1 previously associated with ovarian cancer outcome were genotyped in 10,084 invasive cases from 28 studies from the Ovarian Cancer Association Consortium with over 37,000-observed person-years and 4,478 deaths. Cox proportional hazards models were used to examine the association between candidate SNPs and ovarian cancer recurrence or survival with and without adjustment for key covariates. Results: We observed no association between genotype and ovarian cancer recurrence or survival for any of the SNPs examined. Conclusions: These results refute prior associations between these SNPs and ovarian cancer outcome and underscore the importance of maximally powered genetic association studies. Impact: These variants should not be used in prognostic models. Alternate approaches to uncovering inherited prognostic factors, if they exist, are needed. Cancer Epidemiol Biomarkers Prev; 22(5); 987–. ©2013 AACR.